Innovation-Led Growth

Britain has a problem with approval and with adoption. Our research is world class, but the companies it produces too often raise money, run trials and sell their products elsewhere. Capital markets here do not fund the difficult middle stage between a promising idea and a product in the market. Regulation too often rewards caution over risk. The result is that British taxpayers fund the discovery and other countries collect the jobs.

Marc has worked at every stage of that journey: in university labs, in start-ups, and in a large pharmaceutical company. Through his own firm, he backs British science and technology founders and has helped them raise millions in early-stage funding. He has watched products developed in Britain, with British clinical partners, taken up abroad years before they were used here.

He wants practical support for small companies making the jump from idea to product, a regulatory system that is rigorous but predictable, and an honest look at what countries such as Singapore, Germany and the United States do to turn research into industry. Clinical trials should be something Britain competes to attract, not something it lets drift overseas.

Growth will not come from managing decline more efficiently. It will come from building things here again.